Nesuparib is under clinical development by Onconic Therapeutics and currently in Phase II for Peritoneal Cancer. According to GlobalData, Phase II drugs for Peritoneal Cancer have a 37% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Nesuparib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Nesuparib overview

JPI-547 (NOV-1402) is under development for the treatment of fallopian tube cancer, primary peritoneal cancer and non-small cell lung cancer. The drug candidate is administered orally. It acts by targeting poly (ADP-ribose) polymerase 1,2 and 3 (PARP) 1and tankyrase (TNKS). It is a new molecular entity (NME).

It was also under development for  solid tumors including colorectal cancer, advanced or metastatic pancreatic ductal adenocarcinoma (PDAC), high grade serous ovarian cancer, triple negative breast cancer, castration-resistant prostate cancer, gastric cancer.

Onconic Therapeutics overview

Onconic Therapeutics., is a provider of drug development services. The company is headquartered Republic of Korea (South Korea).

For a complete picture of Nesuparib’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.